# Alaria (Alaria esculenta)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/alaria
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Marine-Derived
**Also Known As:** Alaria esculenta, winged kelp, badderlocks, Atlantic wakame, European kelp, Irish wakame, North Atlantic alaria

## Overview

Alaria esculenta is a brown seaweed rich in fucoidan, phlorotannins, and omega-3 fatty acids that exert [antioxidant](/ingredients/condition/antioxidant), [neuroprotective](/ingredients/condition/cognitive), and [anti-inflammatory](/ingredients/condition/inflammation) effects. Its bioactive polyphenols and sulfated polysaccharides interact with protein aggregation pathways and [cellular senescence](/ingredients/condition/longevity) mechanisms relevant to aging and neurodegeneration.

## Health Benefits

• May support [brain health](/ingredients/condition/cognitive) by modulating α-synuclein folding and inhibiting amyloid formation relevant to Parkinson's disease (in vitro evidence only, PMID: 28237800)
• Shows potential [anti-aging](/ingredients/condition/longevity) properties by reducing progerin production in aged skin cells (in vitro evidence only, PMID: 21535442)
• Demonstrates [antimicrobial](/ingredients/condition/immune-support) activity against E. coli and L. innocua through polysaccharide-rich extracts (in vitro evidence only, PMID: 39852548)
• May support metabolic health through ACE-1, α-amylase, and lipase inhibition (in vitro evidence only, PMC11764973)
• Contains [antioxidant](/ingredients/condition/antioxidant) compounds with ABTS radical scavenging activity, particularly in March/April harvests (in vitro evidence only)

## Mechanism of Action

Fucoidan and phlorotannin compounds in Alaria esculenta inhibit α-synuclein amyloid fibril formation, likely by binding to the hydrophobic regions of the protein and preventing nucleation, a key pathological step in Parkinson's disease. Its polyphenolic extracts have been shown to suppress progerin accumulation in dermal fibroblasts, possibly by modulating lamin A processing and reducing [oxidative stress](/ingredients/condition/antioxidant) via Nrf2 pathway activation. Additionally, fucoxanthin, a marine carotenoid present in the seaweed, may inhibit NF-κB signaling to dampen [pro-inflammatory cytokine](/ingredients/condition/inflammation) production.

## Clinical Summary

Evidence for Alaria esculenta's health effects is currently limited to in vitro laboratory studies with no completed human clinical trials specifically on this species. One cell-based study (PMID: 28237800) demonstrated that Alaria extract modulated α-synuclein folding and reduced amyloid fibril formation relevant to Parkinson's disease pathology, though mechanistic translation to humans remains unestablished. A separate in vitro study (PMID: 21535442) found that the extract reduced progerin production in aged human skin fibroblasts, suggesting [anti-aging](/ingredients/condition/longevity) cellular effects, but again without in vivo confirmation. The overall evidence base is preclinical and preliminary, and clinical efficacy in humans cannot be confirmed at this time.

## Nutritional Profile

Alaria esculenta (winged kelp) is a nutrient-dense brown macroalga with the following documented compositional profile (values expressed on dry weight basis unless noted): Protein: 11–23% DW, containing all essential amino acids with notable concentrations of glutamic acid, aspartic acid, and alanine; protein digestibility is moderate (~70–80%) due to cell wall matrix interactions. Carbohydrates: 40–60% DW total, dominated by alginic acid (15–30% DW), fucoidan (5–15% DW, a sulfated fucose-rich polysaccharide), laminarin (variable, 1–8% DW, a β-1,3-glucan), and mannitol (5–12% DW as a soluble sugar alcohol). Dietary fiber: 30–45% DW, predominantly insoluble alginates and soluble fucoidans; fiber fermentability is limited in humans due to lack of specific gut enzymes for alginate degradation. Lipids: 1–5% DW, with a favorable omega-3 to omega-6 ratio; EPA (eicosapentaenoic acid, 20:5n-3) constitutes approximately 25–40% of total fatty acids, with minimal DHA; total lipid content is low but bioavailability of omega-3s is considered moderate. Iodine: exceptionally high, ranging from 400–2200 µg/g DW (species and season dependent), far exceeding recommended daily intake in small servings; a critical safety consideration. Iodine bioavailability is high (~>90%). Calcium: 600–1200 mg/100g DW; bioavailability reduced by alginate and oxalate binding. Magnesium: 400–700 mg/100g DW. Iron: 15–50 mg/100g DW; non-heme iron with bioavailability estimated at 5–10%, further inhibited by phytate and alginate co-binding. Potassium: 5000–8000 mg/100g DW. Sodium: 2000–4500 mg/100g DW. Phosphorus: 200–500 mg/100g DW. Vitamins: Vitamin C (ascorbic acid): 20–100 mg/100g fresh weight (highly variable, degrades rapidly post-harvest); Vitamin K1: present at ~100–400 µg/100g DW; B-vitamins including riboflavin (B2): ~0.3–0.5 mg/100g DW, niacin (B3): ~1–3 mg/100g DW, and pantothenic acid (B5) in trace amounts; Vitamin B12: present in analogue forms (pseudocobalamin) that are largely inactive in human [metabolism](/ingredients/condition/weight-management) and should not be considered a reliable B12 source. Vitamin A precursors: fucoxanthin (a xanthophyll carotenoid) is the dominant pigment at 0.1–1.0 mg/g DW and is structurally distinct from beta-carotene; it undergoes partial conversion to fucoxanthinol in the gut with moderate bioavailability enhanced by dietary fat. Bioactive compounds: Phlorotannins (polymeric phloroglucinol compounds): 0.5–5% DW, with [antioxidant](/ingredients/condition/antioxidant) ORAC values comparable to terrestrial polyphenols; bioavailability is considered low due to large molecular size and sulfation. Fucoidan: exhibits documented biological activity in vitro (anticoagulant, [immunomodulatory](/ingredients/condition/immune-support), antiviral); oral bioavailability is uncertain with evidence of partial intestinal absorption of low-molecular-weight fractions. Mannitol: readily absorbed as a sugar alcohol with low glycemic impact. Heavy metal consideration: Alaria esculenta may bioaccumulate arsenic (predominantly as organoarsenicals such as arsenosugars, considered less toxic than inorganic arsenic, ~10–60 µg/g DW total arsenic), cadmium, and lead at levels requiring sourcing and processing controls.

## Dosage & Preparation

No clinically studied dosages are available as no human trials exist. In vitro studies used unspecified concentrations of aqueous extracts. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Alaria esculenta has a long history of dietary consumption in coastal European and Asian populations, suggesting reasonable food-level safety, but concentrated supplement forms have not been rigorously evaluated in clinical trials. Its high iodine content poses a risk of [thyroid](/ingredients/condition/hormonal) dysfunction, particularly in individuals with pre-existing thyroid conditions such as Hashimoto's thyroiditis or hyperthyroidism, and excessive intake may precipitate iodine-induced hypothyroidism or hyperthyroidism. Fucoidan constituents may have anticoagulant properties and could interact with blood-thinning medications such as warfarin or aspirin, increasing bleeding risk. Pregnant or breastfeeding women should use caution due to potential excessive iodine exposure affecting fetal thyroid development, and supplemental use should be discussed with a healthcare provider.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on Alaria esculenta. All available evidence comes from in vitro studies including α-synuclein modulation (PMID: 28237800), progerin reduction in aged skin cells (PMID: 21535442), and [antimicrobial](/ingredients/condition/immune-support) activity assessments (PMID: 39852548).

## Historical & Cultural Context

No historical or traditional medicine uses are documented in available research. Alaria esculenta is consumed as an edible seaweed in European cuisines and is primarily farmed for modern food and biomedical applications.

## Synergistic Combinations

Fucus vesiculosus, Ascophyllum nodosum, Laminaria digitata, Omega-3 fatty acids, Vitamin D

## Frequently Asked Questions

### What is Alaria esculenta used for in supplements?

Alaria esculenta is used in supplements primarily for its fucoidan, phlorotannins, and fucoxanthin content, which are studied for neuroprotective, anti-aging, and antioxidant properties. Preliminary in vitro research suggests potential benefits in reducing α-synuclein aggregation linked to Parkinson's disease and slowing cellular aging markers like progerin, though no human trials have confirmed these effects.

### Does Alaria esculenta help with Parkinson's disease?

In vitro evidence (PMID: 28237800) suggests that Alaria esculenta extracts can inhibit α-synuclein amyloid fibril formation, a process central to Parkinson's disease neurodegeneration, likely through direct polyphenol-protein interactions. However, this research was conducted entirely in cell culture, and there are no human or animal studies confirming therapeutic benefit for Parkinson's disease patients.

### How much iodine is in Alaria esculenta?

Alaria esculenta is one of the higher-iodine brown seaweeds, with reported iodine concentrations ranging from approximately 150 to over 500 µg per gram of dry weight depending on season and harvesting location. The recommended daily intake of iodine for adults is 150 µg, meaning even small amounts of dried Alaria can easily exceed safe upper limits of 1,100 µg per day if consumed in supplement form.

### Can Alaria esculenta slow skin aging?

One in vitro study (PMID: 21535442) found that Alaria esculenta extract reduced the accumulation of progerin, a truncated form of lamin A protein associated with accelerated cellular aging, in aged human dermal fibroblasts. This suggests a potential mechanism for slowing intrinsic skin aging at the cellular level, but the findings have not been replicated in human clinical trials or controlled skincare studies.

### Is Alaria esculenta the same as wakame?

No, Alaria esculenta is not the same as wakame, though both are brown seaweeds in the order Laminariales and share some nutritional similarities. Wakame refers to Undaria pinnatifida, a Pacific seaweed widely consumed in Japanese cuisine, whereas Alaria esculenta is a North Atlantic species sometimes called 'Atlantic wakame' or 'dabberlocks' due to its similar appearance and culinary uses.

### What is the difference between Alaria esculenta and other kelp supplements in terms of iodine content and safety?

Alaria esculenta typically contains 400–8,600 mcg of iodine per gram of dried seaweed, which is significantly higher than many other kelp species and can exceed safe daily intake limits if not properly dosed. Unlike some brown algae supplements, Alaria esculenta's iodine content varies based on harvest location and water conditions, making standardized dosing challenging. Individuals with thyroid conditions or those taking thyroid medications should consult a healthcare provider before use to avoid iodine overload.

### Is Alaria esculenta safe for people taking anticoagulant or antiplatelet medications?

Alaria esculenta contains fucoidans and other polysaccharides that may have mild anticoagulant properties, raising theoretical concerns for individuals on blood thinners like warfarin or aspirin. While no direct clinical interactions have been formally documented, the high iodine content may also affect thyroid function and indirectly interact with medications metabolized by the thyroid. Anyone on anticoagulant therapy should inform their healthcare provider before adding Alaria esculenta supplements.

### What does the current clinical evidence actually show about Alaria esculenta's benefits, and is it ready for human use?

Most evidence for Alaria esculenta's benefits—including effects on Parkinson's disease markers and skin aging—comes from in vitro (test tube) and animal studies, not human clinical trials. These early-stage findings are promising but cannot yet be translated to real-world supplement efficacy or safety in humans. Consumers should understand that current marketing claims significantly outpace the strength of available research, and human trials are needed before strong health recommendations can be made.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*